How should a 59-year-old woman with portal hypertension and esophageal varices, polycythemia vera on hydroxyurea, marked splenomegaly (~27 cm), anemia (hemoglobin 7 g/dL), night sweats and intermittent fever, peripheral blood smear showing 2% blasts and bone marrow without fibrosis be managed?

Management Recommendation

This patient requires immediate discontinuation of hydroxyurea, urgent evaluation for post-polycythemia vera myelofibrosis (PPV-MF), and consideration of ruxolitinib as second-line therapy, while simultaneously managing her portal hypertension with endoscopic variceal surveillance and prophylaxis.

Critical Assessment: Likely Disease Transformation

This clinical picture strongly suggests post-polycythemia vera myelofibrosis (PPV-MF). The patient meets diagnostic criteria from the International Working Group 1:

Required criteria present:

• Previous diagnosis of polycythemia vera
• Massive splenomegaly (27 cm is extreme)

Additional criteria present (≥2 required):

• Anemia with loss of phlebotomy requirement (Hgb 7 g/dL)
• Constitutional symptoms (night sweats, fever for 2 months)
• Marked splenomegaly
• Peripheral blood blasts (2%)

The absence of bone marrow fibrosis does NOT exclude PPV-MF in early stages, though repeat bone marrow biopsy with reticulin staining should be performed to confirm grade 2-3 fibrosis.

Immediate Actions Required

1. Stop Hydroxyurea NOW

The FDA label explicitly states hydroxyurea causes severe myelosuppression and should be discontinued when bone marrow function is markedly depressed 2. With Hgb 7 g/dL and 2% peripheral blasts, continuing hydroxyurea is contraindicated. Additionally, evaluate for hemolytic anemia (LDH, haptoglobin, reticulocyte count, Coombs test) as hydroxyurea can cause this complication 2.

2. Initiate Ruxolitinib

For hydroxyurea-resistant/intolerant PV with massive splenomegaly and constitutional symptoms, ruxolitinib is the evidence-based second-line therapy 3, 4, 5. The European observational study showed 68.2% achieved hematocrit control and 85.1% eliminated phlebotomy requirements at 24 months 3. Ruxolitinib specifically addresses:

• Massive splenomegaly (your patient's most prominent feature)
• Constitutional symptoms (night sweats, fever)
• Cytopenia management in transformed disease

Dosing consideration: Start conservatively given severe anemia; monitor closely for worsening cytopenias.

3. Portal Hypertension Management

Despite non-cirrhotic portal hypertension (NCPH), this patient requires aggressive variceal management. The case series of PV with NCPH showed that 4 of 5 patients had moderate-severe esophageal varices 6.

Immediate steps:

• Urgent upper endoscopy if not recently performed (within 3 months)
• Primary prophylaxis with non-selective beta-blockers (carvedilol or propranolol) if large varices present 7
• Endoscopic variceal ligation (EVL) if high-risk varices identified
• Avoid aspirin temporarily until variceal status clarified and bleeding risk assessed, especially with platelet dysfunction from extreme thrombocytosis if present

Critical caveat: The patient faces dual competing risks—thrombosis from PV and bleeding from varices. Once varices are adequately treated/banded, resume low-dose aspirin for thrombosis prevention 4, 5.

4. Evaluate for Portal Vein Thrombosis

Three of five patients in the PV-NCPH case series had portal vein thrombosis with cavernous transformation 6. Your patient's CT was reportedly normal except splenomegaly, but specifically review for:

• Portal vein patency and flow
• Splenic vein thrombosis
• Cavernous transformation

If thrombosis present, anticoagulation must be carefully balanced against variceal bleeding risk—consider TIPS if refractory bleeding occurs 7.

Diagnostic Workup to Complete

1. Repeat bone marrow biopsy with reticulin/trichrome staining to grade fibrosis definitively
2. JAK2 V617F allele burden if considering interferon as alternative
3. Cytogenetic analysis and molecular panel (spliceosome mutations, abnormal karyotype predict worse outcomes) 5
4. Hemolysis workup (LDH, haptoglobin, indirect bilirubin, reticulocyte count, Coombs) 2
5. Lactate dehydrogenase (elevated in PPV-MF) 1

Alternative Second-Line Options (if ruxolitinib unavailable/contraindicated)

Pegylated interferon-α is an alternative second-line agent 8, 5, particularly if:

• Patient is younger with long life expectancy
• Concern about leukemic transformation risk
• Ruxolitinib-induced cytopenias are prohibitive

However, interferon may worsen constitutional symptoms initially and requires months for response.

Busulfan is mentioned as second-line 5 but carries leukemogenic risk and is generally reserved for elderly patients unsuitable for other therapies.

Monitoring Strategy

• Weekly CBC initially after starting ruxolitinib (anemia is most common adverse event at 22.6%) 3
• Endoscopy every 6-12 months for variceal surveillance 6
• Clinical assessment for progression to acute leukemia (blast percentage, constitutional symptoms)
• Spleen size monitoring (clinical exam, imaging every 3-6 months)

Prognosis Discussion

With PPV-MF transformation, median survival is significantly reduced compared to stable PV. The 10-year leukemic transformation rate for PV is approximately 3% 5, but presence of peripheral blasts (2%) warrants close monitoring. The combination of NCPH and myelofibrosis creates complex management challenges requiring hematology-hepatology co-management.

Key pitfall to avoid: Do not restart hydroxyurea in this setting of severe anemia and possible disease transformation. The myelosuppression will worsen outcomes and quality of life dramatically 2.